SCHEMBL6487898

SCHEMBL6487898

CCOC(=O)CCCOc1ccc(N)c(NCc2ccc(Cl)cc2Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.42
ALDH1A1 P00352 2/20 0.42
TP53 P04637 1/20 0.42
BRD4 O60885 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
HPGD P15428 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
PABPC1 P11940 1/20 0.41
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
P2RY12 Q9H244 1/20 0.41
CNR1 P21554 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
NPC1 O15118 1/20 0.40
CD38 P28907 1/20 0.40
PDK2 Q15119 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6501801 0.87 HDAC1 (0.44) MAPTALDH1A1TP53BRD4HDAC1
SCHEMBL6489796 0.87 MAPT (0.42) MAPTALDH1A1TP53BRD4HDAC1
SCHEMBL6501452 0.83 IDO1 (0.41) MAPTALDH1A1TP53BRD4HDAC1
SCHEMBL6497406 0.80 BRD4 (0.41) MAPTBRD4MEN1KMT2ATDP1
SCHEMBL7068046 0.80 HDAC1 (0.39) HDAC1HDAC8HDAC6MEN1KMT2A
SCHEMBL6501526 0.78 HDAC1 (0.39) MAPTALDH1A1TP53BRD4HDAC1
SCHEMBL6171173 0.78 HDAC1 (0.56) MAPTALDH1A1HDAC1HDAC8HDAC6
SCHEMBL6490287 0.78 HDAC1 (0.39) MAPTALDH1A1TP53BRD4HDAC1
SCHEMBL20715677 0.76 MAPT (0.51) MAPTHDAC8TDP1L3MBTL1
SCHEMBL7068049 0.74 CD38 (0.40) ALDH1A1HDAC1HDAC8HDAC6TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD MAPT 3168/4885ALDH1A1 96/4885TP53 1741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.